Drug targeting tumor metabolism discovered by MD Anderson’s Institute for Applied Cancer Science enters clinical trial
The University of Texas MD Anderson Cancer Center’s Institute for Applied Cancer Science (IACS) has initiated the first clinical study of a novel drug designed to starve cancer cells, IACS-10759. The study will enroll patients with acute myeloid leukemia (AML) and is supported by a $3.5 million investment from The Leukemia & Lymphoma Society (LLS) Therapy Acceleration Program®. Recent approval from the U.S. Food and Drug Administration...
American Lung Association and MD Anderson Announce Effort to Improve Tobacco Cessation Treatment for Medicaid Enrollees
The American Lung Association and The University of Texas MD Anderson Cancer Center are pleased to announce a new partnership aimed at increasing...
Tonya Edwards receives MD Anderson’s highest nursing honor
Tonya Edwards, a clinical nurse in Palliative Care at The University of Texas MD Anderson Cancer Center, is the recipient of the 2016 Brown...
MD Anderson and HISD partner for youth tobacco prevention program
The University of Texas MD Anderson Cancer Center and the Houston Independent School District (HISD) have reached a first-of-its-kind agreement to provide access to an evidence-based, youth-oriented tobacco prevention and cessation program for all 110,000 HISD middle and high school students. A Smoking Prevention Interactive Experience (ASPIRE) will be made available in English and Spanish through HISD’s online learning and teaching platform...
MD Anderson study identifies significant cost differences between breast cancer chemotherapy regimens
Costs associated with different breast cancer chemotherapy regimens can vary significantly, regardless of effectiveness, according to new...
MD Anderson-led study finds ribociclib improves progression-free survival for women with metastatic breast cancer
In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, ribociclib, in combination with...
Frontline PARP inhibitor shrinks tumors in BRCA-positive breast patients
All 13 newly diagnosed breast cancer patients with BRCA mutations had their tumors shrink significantly when treated with a PARP inhibitor...